Area of research
Immunology · Genetics
Research interest
His work over the past 30 years has been in the field of T-cell activation, co-stimulation, and immune tolerance research. The efforts in his lab have led to the development of multiple pro-tolerogenic immunotherapies, including CTLA4Ig, the first FDA-approved drug targeting T-cell co-stimulation to treat autoimmune disease and organ transplantation; a novel anti-human CD3 antibody being developed to treat type 1 diabetes (T1D); and the first CTLA-4 antagonist drugs approved for the treatment of metastatic melanoma. In recent years, he has focused on the field of regulatory T cells, understanding their biology and use in the control of autoimmunity and cancer including several seminal studies to determine mechanisms and control Treg stability. These efforts in translational research have led to over 400 peer-reviewed publications as well as multiple basic research and clinical research grant awards.
Pharmacology and nonclinical development of teplizumab, a first-in-class immunotherapy for delaying the onset of type 1 diabetes
Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study
The extra-islet pancreas supports autoimmunity in human type 1 diabetes.
The extra-islet pancreas supports autoimmunity in human type 1 diabetes
Regulatory T cell therapies to treat autoimmune diseases and transplant rejection.
POS0034 REGULATE-RA: A Phase 1 Study of CAR-T Regulatory Cells Targeting Citrullinated Proteins in Refractory Rheumatoid Arthritis: Interim Safety and Tolerability
Harnessing regulatory T cells to establish immune tolerance
Harnessing regulatory T cells to establish immune tolerance.
Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis
Multiple early factors anticipate post-acute COVID-19 sequelae
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies
Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies.
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection
The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
Immunotherapy: Building a bridge to a cure for type 1 diabetes
Immunotherapy: Building a bridge to a cure for type 1 diabetes.
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance
Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance
Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19
T<sub>reg</sub> cell-based therapies: challenges and perspectives.
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.
Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency.
CRISPR screen in regulatory T cells reveals modulators of Foxp3
CRISPR screen in regulatory T cells reveals modulators of Foxp3.
Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies